GlassScriptPhysician profile
Cassandra Mance
NPI 1649853219
$551.02
in general payments reported to CMS, 2019-2025
17 companies · $88.99 in 2025
The $88.99 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.05 · 2022: $128 · 2023: $171 · 2024: $137 · 2025: $88.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $65.97 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $59.86 | 2024-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $49.85 | 2023-2025 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $36.97 | 2023 | |
| Genentech USA, INC. | $35.93 | 2024-2025 | Itovebi |
| Abbvie INC. | $34.50 | 2023-2024 | |
| Seagen INC. | $22.21 | 2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $20.49 | 2025 | Imfinzi |
| Pharmacosmos Therapeutics INC. | $20.33 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $20.24 | 2023 | Jemperli, Zejula |
| Gilead Sciences, INC. | $20.22 | 2024 | |
| Recordati_rare_diseases_inc. | $18.08 | 2024 | Sylvant |
| Adc Therapeutics America, INC. | $16.44 | 2023 | |
| Blueprint Medicines Corporation | $16.42 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.30 | 2023 | Jaypirca, Verzenio |
| Epizyme, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Mance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.